ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 409,11
0,80%
Dow Jones
42 052,19
0,69%
DAX
19 254,97
1,03%
Brent Oil
72,905
0,00%
Bitcoin
69 468,30
-0,02%
Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. USOTC

  6. Sorrento Therapeutics Inc (CE) (SRNE) Cours

Sorrento Therapeutics Inc (CE)

Sorrento Therapeutics Inc (CE) (SRNE)

USOTC
0,0027
0,00
(0,00%)
Fermé 02 Novembre 9:00PM
Retardé de 15 minutes

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Premium

Statistiques et détails clés

Dernier
0,0027
Prix Achat
0,00
Prix Vente
0,00
Volume échangé
128 974
0,0006 Fourchette du Jour 0,003
0,0001 Plage de 52 semaines 0,0925
Clôture Veille
0,0027
Ouverture
0,0006
Dernière Transaction
4
@
0.0027
Dernière heure de transaction
Volume moyen (3 m)
188 046
Volume financier
US$ 284
VWAP
0,002204

SRNE Dernières nouvelles

Plus de nouvelles

Sorrento Therapeutics Announces Full Exercise of Over-Allotment Option

Sorrento Therapeutics Announces Full Exercise of Over-Allotment Option PR Newswire SAN DIEGO, Oct. 25, 2013 SAN DIEGO, Oct. 25, 2013 /PRNewswire/ -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE...

25 Octobre 2013
PR Newswire (US)

Sorrento Therapeutics Acquires Clinical Stage Drug Candidate for Treatment of Chronic Pain

Sorrento Therapeutics Acquires Clinical Stage Drug Candidate for Treatment of Chronic Pain PR Newswire SAN DIEGO, Oct. 10, 2013 SAN DIEGO, Oct. 10, 2013 /PRNewswire/ -- Sorrento Therapeutics...

11 Octobre 2013
PR Newswire (US)

Sorrento Therapeutics Announces a Presentation on Cynviloq™ at the AACR Conference on Advances in Ovarian Cancer Research: ...

Sorrento Therapeutics Announces a Presentation on Cynviloq™ at the AACR Conference on Advances in Ovarian Cancer Research: From Concept to Clinic PR Newswire SAN DIEGO, Sept. 16, 2013 SAN DIEGO...

16 Septembre 2013
PR Newswire (US)

Sorrento Therapeutics Secures Rights to Biomiga Diagnostics' Therapeutic Drug Monitoring Device for Development of Personaliz...

Sorrento Therapeutics Secures Rights to Biomiga Diagnostics' Therapeutic Drug Monitoring Device for Development of Personalized Paclitaxel Cancer Therapy PR Newswire SAN DIEGO, Sept. 10, 2013 SAN...

10 Septembre 2013
PR Newswire (US)

Sorrento Therapeutics Completes IgDraSol Merger

Sorrento Therapeutics Completes IgDraSol Merger PR Newswire SAN DIEGO, Sept. 10, 2013 SAN DIEGO, Sept. 10, 2013 /PRNewswire/ -- Sorrento Therapeutics, Inc. (OTC QB: SRNE; Sorrento) announced...

10 Septembre 2013
PR Newswire (US)

Sorrento Therapeutics and IGDRASOL Proceed with Development of Cynviloq™ under 505(b)(2) Bioequivalence Regulatory Pathway

Sorrento Therapeutics and IGDRASOL Proceed with Development of Cynviloq™ under 505(b)(2) Bioequivalence Regulatory Pathway Official Minutes from End-of-Phase 2 FDA Meeting Provide Clarity on Next...

05 Août 2013
PR Newswire (US)

Sorrento Therapeutics Announces Reverse Split of Common Stock

Sorrento Therapeutics Announces Reverse Split of Common Stock PR Newswire SAN DIEGO, Aug. 1, 2013 SAN DIEGO, Aug. 1, 2013 /PRNewswire/ -- Sorrento Therapeutics, Inc. (OTCQB: SRNE; Sorrento...

01 Août 2013
PR Newswire (US)

Sorrento Therapeutics, Inc. and IGDRASOL Will Present Preliminary Phase III Data Analysis for Cynviloq at the 4th Internation...

Sorrento Therapeutics, Inc. and IGDRASOL Will Present Preliminary Phase III Data Analysis for Cynviloq at the 4th International Nanomedicine Conference in Sydney, Australia PR Newswire SAN DIEGO...

01 Juillet 2013
PR Newswire (US)

Sorrento Therapeutics Receives Frost & Sullivan's Prestigious 2013 Global Investment Opportunity Award in the Oncology Market

Sorrento Therapeutics Receives Frost & Sullivan's Prestigious 2013 Global Investment Opportunity Award in the Oncology Market PR Newswire MOUNTAIN VIEW, California, June 6, 2013 MOUNTAIN...

06 Juin 2013
PR Newswire (US)
PériodeVariationVariation %Ouver.HautBasMoyenne Vol. Quot.VWAP
10.000628.57142857140.00210.0040.00064098280.00364569CS
40.00213500.00060.010.00062674640.00339916CS
120.00224400.00050.09250.00051880460.00517284CS
26-0.0108-800.01350.09250.00021456770.00753052CS
52-0.0133-83.1250.0160.09250.00011559860.01043147CS
156-7.8573-99.9656488557.867.860.00011506070.01043147CS
260-7.8573-99.9656488557.867.860.00011475540.01043147CS

Moteurs

Voir tout
  • Volume
  • % Gagnants
  • % Perdants
SymbolePrixVol.
GAPJGolden Apple Oil and Gas Inc (CE)
US$ 0,001
(99 900,00%)
130
ERHEERHC Energy Inc (CE)
US$ 0,001
(99 900,00%)
5,11M
BLIAQBB Liquidating Inc (CE)
US$ 0,001
(99 900,00%)
102,03k
VIPZVIP Play Inc (PK)
US$ 0,75
(62 400,00%)
300
FFRMFFuture Farm Technologies Inc (CE)
US$ 0,000101
(10 000,00%)
1,25k
REPCFRepliCel Life Sciences Inc (CE)
US$ 0,000001
(-99,98%)
2,5k
AHPIQAllied Healthcare Products Inc (CE)
US$ 0,000001
(-99,50%)
1,16k
JUVAFJuva Life Inc (CE)
US$ 0,000001
(-99,00%)
300
DXBRFBellRock Brands Inc (CE)
US$ 0,000001
(-99,00%)
193,88k
MNGGMining Global Inc (PK)
US$ 0,000001
(-99,00%)
4,7M
NSAVNet Savings Link Inc (PK)
US$ 0,0006
(-68,42%)
1,1B
HMBLHUMBL Inc (PK)
US$ 0,0003
(50,00%)
260,3M
RDARRaadr Inc (PK)
US$ 0,001
(-9,09%)
214,52M
NNAXNew Momentum Corporation (PK)
US$ 0,0006
(0,00%)
194,37M
ASIIAccredited Solutions Inc (PK)
US$ 0,0009
(0,00%)
138,32M

Forums

Afficher les forums
Aucune Discussion Trouvée
Ajouter une Discussion

Dernières Valeurs Consultées

USOTC
SRNE
Sorrento Therapeutics (CE)
BIT
P21RB1
NLBNPIT21RB1 20241220 22
AQSE
IDTM.GB
iShares USD Treasury Bon...
COIN
CMCTUSD
Crowd Machine Compute Token
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés